Journal
JOURNAL OF INFECTION
Volume 84, Issue 1, Pages 1-7Publisher
W B SAUNDERS CO LTD
DOI: 10.1016/j.jinf.2021.10.017
Keywords
Bloodstream infection; Febrile neutropenia; Acute myeloid leukemia; Appropriate use of antibiotics
Categories
Ask authors/readers for more resources
This study compared the efficacy of short versus prolonged antibiotic treatment for bloodstream infection (BSI) in acute myeloid leukemia (AML) patients. The findings suggest that short-term antibiotic treatment is as effective as prolonged treatment, with very few relapses within 30 days of discontinuation.
S U M M A R Y Objectives: There is no specific recommendation about antimicrobial treatment length for documented infections in chemotherapy induced febrile neutropenia (FN). Practices have changed along time in our center regarding length of antibiotic treatment. The aim of this study was to compare long versus short antibiotic course for bloodstream infection (BSI) treatment in acute myeloid leukemia (AML) patients during FN. Methods: This monocentric retrospective comparative study included all consecutive BSI episodes among AML patients with FN for 3 years (2017-2019). Episodes were classified regarding the length of antibiotic treatment, considered as short course if the treatment lasted < 7 days, except for nonfermenting bacteria and Staphylococcus aureus or lugdunensis for which the threshold was < 10 days and < 14 days, respectively. The primary outcome was the number of BSI relapses in both groups within 30 days of antibiotic discontinuation. Results: Among 71 AML patients, 104 BSI episodes were included; 48 (46%) received short course treatment. Only 8 (7.6%) BSI episodes relapsed within 30 days of antibiotic discontinuation, 5 having received short course treatment. No association was found between risk of relapse and short course of antibiotic treatment ( p = 0.37). The only risk factor significantly associated with BSI relapse was neutropenia duration ( p = 0.005). Conclusion: Antibiotic short course seemed as effective as prolonged treatment for BSI in AML patients during FN, with very few relapses at day 30. These encouraging findings should be confirmed through prospective studies. (c) 2021 The British Infection Association. Published by Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available